Kinase inhibitor
Phase 2Small molecule
Kinase inhibitor is one of 67 small molecule programs targeting Toxicity. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
62 competitors in Toxicity
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Zyvox
PfizerApproved
Oncovin
Eli LillyApproved
Aldactone
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Prezista
WWim Janssens
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Kinase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmunocore Ltd